

providing a cyclic lipopeptide, a salt of the lipopeptide, an ester of the lipopeptide, or a mixture thereof;

contacting said product[, serum-free cell cultures or serum-containing cell cultures] with the cyclic lipopeptide, salt of the lipopeptide, ester of the lipopeptide, or mixture thereof as an inactivating agent, at room temperature for 30 minutes up to 2 hours, wherein

[a)] the agent is added to said products at a concentration of 1-100  $\mu\text{M}$  and an inactivation factor  $> 10^4$  is achieved [when inactivating viruses in the products; and wherein

b) the agent is added to serum-free culture medium at a concentration of 1-65  $\mu\text{M}$ , or to serum-containing culture medium at a concentration of 10-100  $\mu\text{M}$ , when inactivating viruses in cell medium].

15. (Amended) The method of claim 10, wherein the herpes [viruses] virus is herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), bovine herpes virus type 1 (BHV-1) or suid herpes virus type 1 (SHV-1).

[ Please add the following new claims.]

18. The method of claim 1, wherein the non-cell culture biological products are selected from the group consisting of blood products, products isolated from blood, and bio-technological pharmaceutical products consisting of human proteins.

19. The method of claim 18, wherein the products isolated from blood are